[{"id":"c2490533-cc94-4293-b9b1-7cb177414cff","acronym":"","url":"https://clinicaltrials.gov/study/NCT03308201","created_at":"2021-01-18T16:20:20.019Z","updated_at":"2024-07-02T16:35:16.220Z","phase":"Phase 1","brief_title":"Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer","source_id_and_acronym":"NCT03308201","lead_sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 overexpression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • letrozole • exemestane • sacibertinib (Hemay022)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 10/16/2017","start_date":" 10/16/2017","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2024-03-06"},{"id":"2eecf85d-a79b-41e0-8ca5-25f9e0bc133d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02476539","created_at":"2021-01-18T11:55:27.109Z","updated_at":"2024-07-02T16:35:16.815Z","phase":"Phase 1","brief_title":"Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer","source_id_and_acronym":"NCT02476539","lead_sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sacibertinib (Hemay022)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 10/14/2015","start_date":" 10/14/2015","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 09/30/2023","study_completion_date":" 09/30/2023","last_update_posted":"2024-03-01"},{"id":"6df720ef-c45f-4be6-8596-e27253e787e5","acronym":"Fillful-03","url":"https://clinicaltrials.gov/study/NCT05122494","created_at":"2021-11-16T12:53:44.063Z","updated_at":"2024-07-02T16:36:07.678Z","phase":"Phase 3","brief_title":"A Phase Ⅲ Study of the Efficacy and Safety of Hemay022+Aromatase Inhibitor(AI) in Participants With ER+/HER2+ Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05122494 - Fillful-03","lead_sponsor":"Tianjin Hemay Oncology Pharmaceutical Co., Ltd","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 overexpression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib • capecitabine • sacibertinib (Hemay022)"],"overall_status":"Recruiting","enrollment":" Enrollment 339","initiation":"Initiation: 01/19/2022","start_date":" 01/19/2022","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2022-07-06"}]